Before and during that kind of treatment, a clinician commonly reviews bloodwork, including Hemoglobin A1C, a lipid panel, and kidney and liver markers. This page is educational and not medical advice.
A peptide is a short chain of amino acids, longer than a single amino acid and shorter than a full protein, that the body uses as a signal rather than as structural material. Many hormones are peptides. They bind to receptors on cells, change what those cells do for a while, and are then broken down.
One of those natural signals is glucagon-like peptide 1, a gut hormone released after eating that acts on the pancreas, the stomach and the brain 1. It belongs to the incretin hormones, gut hormones released in response to food that increase insulin release after a meal 2. In other words, your body already runs an appetite and glucose signalling system built out of peptides, and it runs it every time you eat.
Peptide medicines are designed to copy or extend a signal the body already uses. Natural gut peptides are cleared within minutes, so medicines in this space are engineered to last far longer in circulation. Because peptides are digested like any other protein when swallowed, the weight-related ones are given by injection rather than as a tablet.
That is the useful mental model. A peptide medicine is not a fat burner and not a stimulant. It is a signal, and the question that matters is whether that specific signal has been studied in people, at what strength, and with what trade-offs. This page names classes only, never a product, brand or compound, and gives no doses, schedules or administration steps, because those belong to a licensed prescriber.
One group stands apart: the prescription incretin class, meaning GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists 5.
A systematic review, meta-analysis and meta-regression of 47 randomized controlled trials reported reductions in body weight, BMI and waist circumference in patients with obesity or overweight using GLP-1 receptor agonists 3. A clinical review of the class in adults describes its use in weight management and glucose control 4.
Everything else sold under the "peptide" banner for fat loss sits in a different category, covered further down. The table below sets out the difference plainly.
| Option type | What human data supports | Who can provide it |
|---|---|---|
| Prescription incretin class (GLP-1 receptor agonists, dual GIP/GLP-1 receptor agonists) | Pooled randomized trials in adults with obesity or overweight report reductions in body weight, BMI and waist circumference 3 | A licensed provider, after an evaluation |
| Other peptides marketed online for fat loss | No comparable human support; many are not approved for the uses they are marketed for | Not appropriate to self-source |
| Compounded or "lab-grade" peptide products | Quality, purity and labelling accuracy vary between sources | Not appropriate to self-source |
Naming the class is as specific as this page goes. Which medicine within a class, whether any of them fits a given person, and whether the person should start at all are decisions a licensed prescriber makes after reviewing history, current medicines and labs.
They amplify a signalling system your gut already uses after a meal. Glucagon-like peptide 1 acts on receptors in the pancreas, the gut and the brain, slowing gastric emptying, increasing the sense of fullness and increasing insulin release in a glucose-dependent way 1. The glucose-dependent part matters, because the insulin effect scales with how high blood sugar actually is 2.
The practical result is that food leaves the stomach more slowly and the brain registers satiety earlier and for longer. People describe smaller portions, less interest in snacking, and a quieter internal conversation about food. Research suggests that this appetite and gastric effect is central to how the class produces weight loss 5.
Dual agonists add a second incretin pathway. Glucose-dependent insulinotropic polypeptide is the other main incretin hormone released after eating 2, and medicines engineered to act on both receptors are described as having distinct mechanisms of action from single-receptor agents 5.
Two things follow from the mechanism. First, this is appetite regulation, not fat burning. Energy intake falls because hunger and fullness signalling changes, so what you eat during that smaller intake becomes more important, not less. Second, the same mechanism that creates fullness also explains most of the side effects, since slowing the stomach has predictable consequences.
On average, meaningfully more than with placebo, but with a wide spread between individuals. Pooled across 47 randomized controlled trials, GLP-1 receptor agonists reduced body weight, BMI and waist circumference in adults with obesity or overweight 3. A clinical review of the class describes weight reduction as a core effect in adults 4.
Averages are the wrong number to plan your life around. Among people taking these medicines, some people respond strongly, some respond modestly and some stop early because of side effects. No one can tell you in advance which group you will land in, and nobody should promise you a figure. Outcome promises are a marketing signal, not a clinical one.
It is also worth noting what that supervised setting includes. Participants are screened, monitored and supported, and medicine is layered on top of dietary and activity guidance rather than replacing it. A consensus statement on incretin-based therapies sets out nutritional, functional and psychological considerations that accompany this kind of treatment in adults 7.
Waist circumference deserves a mention of its own. It was one of the outcomes reported in the pooled analysis 3, and it tracks the fat distribution most tied to metabolic markers. If the scale is moving slowly but the waist is changing, that is still information worth bringing to your clinician rather than ignoring.
Gastrointestinal ones, by a wide margin. Use of GLP-1 receptor agonists is associated with gastrointestinal adverse effects, most commonly nausea, vomiting and diarrhoea, in a systematic review and meta-analysis of 99,599 patients 6. A clinical review of the class lists gastrointestinal symptoms among the main tolerability issues in adults 4.
This follows directly from the mechanism. A stomach that empties more slowly produces fullness, and it can also produce nausea, reflux, bloating and constipation, particularly when food volume, fat content or eating speed stays the same as before. Many people find symptoms are most noticeable early on and when anything about their regimen changes.
How symptoms are managed, including any change to a regimen, is a prescriber decision. This page gives no doses, schedules or titration steps, and you should not take guidance of that kind from the internet or from someone else's experience. Report side effects to the provider who prescribed, not to a forum.
Some symptoms warrant prompt contact rather than waiting for a scheduled follow-up: persistent vomiting, inability to keep fluids down, severe or persistent abdominal pain, or signs of dehydration. These are worth discussing with a clinician promptly. A consensus statement on incretin-based therapies also addresses eating behaviour and psychological considerations during treatment, not just physical symptoms 7.
They act on glucose handling directly, independent of weight. Glucagon-like peptide 1 increases insulin secretion in a glucose-dependent manner and suppresses glucagon, which lowers blood glucose after meals 1. The incretin hormones are part of normal post-meal glucose regulation in health and are altered in metabolic disease 2.
Studies indicate that medicines acting on these receptors improve glycaemic control alongside their effect on body weight 5, and a clinical review of the class describes both glucose and weight effects in adults 4.
On the cardiovascular side, a systematic review and meta-analysis of 99,599 patients examined cardiovascular effects and tolerability of GLP-1 receptor agonists 6. That is the kind of large pooled human data that does not exist for peptides sold outside a prescription pathway, and it is one reason clinicians separate the two groups so sharply.
For you as a reader, the takeaway is practical. If a clinician is considering this kind of treatment, glucose and lipid markers are part of the picture before starting and part of how progress is read afterwards. Weight on a scale is one data point. Glycaemic and lipid markers describe what is happening underneath it, and they sometimes move on a different timeline from body weight.
Because the medicine is supplying a signal, not permanently resetting one. When it stops, appetite and gastric emptying drift back toward their previous pattern, and intake usually follows.
This reframes the whole decision. Starting is not a short project with a finish line. It is a question about long-term management of a long-term condition, and the exit plan matters as much as the entry plan. A consensus statement on incretin-based therapies sets out nutritional, functional and psychological support considerations that apply across the course of treatment in adults 7.
Practically, that means the habits built during treatment carry weight later. Protein intake, resistance training, sleep and meal structure are not decorations on top of a medicine. They are what remains when the appetite signal returns to baseline, and they are worth establishing early rather than left until a stop date approaches.
It also means any decision to stop, pause or change belongs with the licensed provider who prescribed, with a plan attached rather than a sudden gap.
When total intake falls sharply, protein and micronutrient intake usually fall with it unless the eating pattern is deliberately rebuilt. A consensus statement on incretin-based therapies addresses nutritional, functional and psychological considerations for adults using this kind of treatment, including dietary adequacy and physical function 7.
Weight lost from the scale is never purely fat. Some of it is lean tissue, and lean tissue is what supports strength, daily function and resting energy expenditure. Two levers reduce that loss: eating enough protein spread across the day, and training against resistance two or more times a week. Neither is exotic, and both get harder to maintain when appetite is low, which is exactly why they need planning rather than willpower.
Fibre, fluid and overall food quality matter for a second reason. Smaller volumes of food, slower gastric emptying and lower fluid intake together make constipation more likely. Spreading fluids across the day, keeping fibre sources in the rotation and eating more slowly are reasonable, low-risk habits that many people find help.
The psychological side is real too, and the same consensus statement treats eating behaviour and psychological considerations as part of care rather than an afterthought 7. Food carries social and emotional weight. When appetite drops suddenly, that relationship changes, and it is a legitimate thing to raise with a clinician.
Because what is known about them in people is thin or absent, and because the products themselves are inconsistent. Many peptides sold online are not approved for the uses they are marketed for. Compounded and so-called lab-grade products vary in quality and purity between sources, and what is printed on a label is not a guarantee of what is in the vial.
Marketing for these products often leans on findings in cells or animals. A result in a dish or a rodent does not establish a benefit in a person. The step from laboratory work to a human outcome is where most promising ideas fail, and skipping that step in a sales page is a claim about hope rather than a claim about people.
Grading what you are being offered is simple enough in practice. Ask whether the product is approved for the use being advertised. Ask who is accountable if something goes wrong. For most peptides marketed for fat loss, the honest answer to the first question is that human data is limited or missing, and that should carry the same weight as a positive finding would.
This is the core argument for going through a licensed provider rather than self-sourcing. A provider evaluates whether any option is appropriate for you, uses a regulated supply chain, monitors labs and symptoms, and can change course. Someone shipping a vial cannot do any of that. Products sold "for laboratory use only" are, by their own labelling, not intended for use in people.
No sports or physique shortcut is implied here either. This page does not cover performance or bodybuilding use of peptides, and nothing in it should be read as encouragement to experiment.
Usually a metabolic and organ-function baseline, repeated over time. The exact panel is the provider's call, but the markers below come up consistently when weight and metabolic health are the focus.
| Marker | What it measures | Why a provider may check it |
|---|---|---|
| Hemoglobin A1C | Average blood glucose across roughly the previous three months | Sets a glucose baseline and tracks change over time |
| Lipid panel | Total cholesterol, LDL, HDL and triglycerides | Weight and dietary change move these markers |
| Kidney markers (creatinine, eGFR, BUN) | How well the kidneys filter | Vomiting, diarrhoea and low fluid intake can affect kidney readings |
| Liver markers (ALT, AST, ALP, bilirubin) | Liver enzyme activity and clearance | Fat in the liver and rapid weight change can move these values |
| Thyroid markers (TSH, free T4) | Thyroid hormone signalling | Helps account for other reasons weight may be changing |
| CBC and ferritin | Red cell measures and iron stores | Intake of iron and other nutrients can fall when appetite drops |
Labs regard 4 to 5.7 % as the typical reference range for Hemoglobin A1C, and reference ranges vary by lab, age and sex. FitScript's optimal range for this marker is 4.6 to 5.3 %, which is an optimization target rather than a diagnostic cut-off.
Read results as observation, then meaning, then next step. A value above a reference range is an observation. It may reflect glucose handling, recent illness, red cell turnover or several other things. What it is not is a diagnosis made from a single number on a single day. The next step is a conversation with a clinician who can see the trend and the rest of the panel. Never ignore a result that sits outside the standard range, and never assume a single suboptimal value tells the whole story.
FitScript's membership is built around repeat biomarker testing, with 150+ biomarkers tested per year, so markers like these are read as trends rather than as isolated snapshots.
A licensed provider decides, after an evaluation, and that decision is not a formality. Prescription options in this space are not suitable for everyone, and suitability depends on far more than a number on a scale.
An evaluation typically covers weight and health history, current medicines and supplements, personal and family medical history, pregnancy status and plans, digestive history, eating patterns and previous attempts at weight management, plus current labs. In people with certain gastrointestinal, pancreatic, thyroid or gallbladder histories, or in people who are pregnant or planning pregnancy, a provider may rule an option out entirely or choose a different direction.
The provider also sets what follow-up looks like: when labs are repeated, how symptoms get reported, and how progress is defined beyond body weight. Blood pressure, waist circumference, strength, sleep and energy are all reasonable things to track, and some of them improve before the scale does.
Nothing here means you need a prescription. Plenty of people improve metabolic markers without one, and plenty of people are not candidates. The point is that the decision sits with a clinician who has examined your full picture, not with an article, a video or a seller. Discuss your results and any treatment option with a clinician or licensed provider before acting on them.
The fundamentals matter more during treatment, not less, because total intake is smaller and every meal has to do more work. A consensus statement on incretin-based therapies frames nutritional and functional support as part of care in adults rather than optional extras 7.
Protein first, at every meal, is the single most useful habit. Resistance training two or more times a week gives the body a reason to keep the muscle it has. Fibre and fluids reduce the odds of constipation. Eating more slowly and stopping earlier fits a stomach that is emptying more slowly. Alcohol is worth a conversation with your provider, since it adds energy without nutrients and can aggravate reflux and nausea.
Sleep and stress belong on the list as well. Short sleep makes appetite regulation harder and training recovery worse, and neither of those helps when the goal is holding on to lean mass while fat mass falls.
The reason to build these habits now is the one covered earlier. Appetite signalling returns toward its previous pattern once a medicine stops, so the structure you build around eating and training is what you keep.
Whenever symptoms are severe, persistent, or outside what your provider told you to expect. Persistent vomiting, inability to keep fluids down, severe or ongoing abdominal pain, signs of dehydration such as dizziness and very dark urine, or severe constipation are all worth discussing with a clinician promptly rather than waiting for the next scheduled visit.
The same applies to lab results. A value that sits outside the standard reference range is a prompt for a conversation, not a reason to panic and not a reason to stop something on your own. Decisions to start, stop, pause or change any prescription belong to the licensed provider who is monitoring you.
It is also worth raising things that do not feel clinical. A sharp loss of interest in food, a low mood, difficulty eating enough protein, or feeling weaker in training are all legitimate reasons to check in, and a consensus statement on incretin-based therapies treats functional and psychological factors as part of ongoing care 7.
FitScript's treatment pages go deeper on the supervised side of this topic: medical weight loss for women and medical weight loss for men describe how a licensed provider approaches weight management, and peptide therapy for men covers how peptide-based options are evaluated and supervised.
The ones worth considering do. They are prescription injectable medicines, and a licensed provider decides whether any of them is appropriate after an evaluation that usually includes bloodwork. Products sold online without a prescription are a different category, and many are not approved for the uses they are advertised for.
It is not a good idea. Compounded and 'lab-grade' products vary in quality and purity, and the label is not a guarantee of what is inside. Working with a licensed provider means a regulated supply, monitoring of your labs and symptoms, and someone accountable if something goes wrong.
A protein supplement is food, used as building material and digested into amino acids. A peptide medicine is a signal designed to bind a specific receptor and change what cells do. That is also why these medicines are injected rather than swallowed, since digestion would break them apart.
Appetite and stomach emptying drift back toward their previous pattern once the medicine stops, and intake usually follows. That is why the long-term plan matters from the start. Ask your prescriber what stopping would look like before you begin, not after.
Commonly Hemoglobin A1C, a lipid panel, and kidney and liver markers, often alongside thyroid markers and a complete blood count. Your provider chooses the panel based on your history. Repeat testing matters more than a single snapshot, because the trend is what shows whether things are moving in the right direction.
That is a decision for a licensed provider, not a self-assessment. Suitability depends on your full health history, current medicines, labs and goals, not on a target weight alone. Some people are not candidates at all, and a provider will say so.
Yes. Total intake falls, so protein, fibre and fluids have to be deliberate, and resistance training two or more times a week helps you hold on to muscle while losing fat. The habits you build are what remain if the medicine ever stops.
Persistent vomiting, not being able to keep fluids down, severe or ongoing abdominal pain, signs of dehydration, or severe constipation are all worth discussing with a clinician promptly. Report symptoms to the provider who prescribed, and never adjust or stop a prescription on your own.